Stroke-Specific Predictors of Major Bleeding in Anticoagulated Patients With Stroke and Atrial Fibrillation: A Nationwide Multicenter Registry-Based Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose The congestive heart failure, hypertension, age, diabetes, previous stroke/transient ischemic attack (CHA2DS2-VASc) and hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol (HAS-BLED) scores have been validated in estimating the risks of ischemic stroke and major bleeding, respectively, in patients with atrial fibrillation (AF). This study investigated stroke-specific predictors of major bleeding in patients with stroke and AF who were taking oral anticoagulants (OACs). Methods Subjects were selected from patients enrolled in the Korean ATrial fibrillaTion EvaluatioN regisTry in Ischemic strOke patieNts (K-ATTENTION) nationwide multicenter registry between 2013 and 2015. Patients were excluded if they were not taking OACs, had no brain imaging data, or had intracranial bleeding directly related to the index stroke. Major bleeding was defined according to International Society of Thrombosis and Haemostasis criteria. Cox regression analyses were performed to assess the associations between clinical variables and major bleeding and Kaplan-Meier estimates were performed to analyze event-free survival. Results Of a total of 3,213 patients, 1,414 subjects (mean age of 72.6 years, 52.5% males) were enrolled in this study. Major bleeding was reported in 34 patients during the median follow-up period of 1.73 years. Multivariable analysis demonstrated that initial National Institutes of Health Stroke Scale scores (hazard ratio [HR] 1.07, p=0.006), hypertension (HR 3.18, p=0.030), persistent AF type (HR 2.51, p=0.016), and initial hemoglobin level (HR 0.74, p=0.001) were independently associated with major bleeding risk. Except for hypertension, these associations remained significant after adjusting for the HAS-BLED score. Intracranial atherosclerosis presented a trend of association without statistical significance (HR 2.21, p=0.050). Conclusions This study found that major bleeding risk was independently associated with stroke-specific factors in anticoagulated patients with stroke and AF. This has the clinical implication that baseline characteristics of patients with stroke and AF should be considered in secondary prevention, which would bring the net clinical benefit of balancing recurrent stroke prevention with minimal bleeding complications.
Abstract
Background and Purpose The congestive heart failure, hypertension, age, diabetes, previous stroke/transient ischemic attack (CHA2DS2-VASc) and hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol (HAS-BLED) scores have been validated in estimating the risks of ischemic stroke and major bleeding, respectively, in patients with atrial fibrillation (AF). This study investigated stroke-specific predictors of major bleeding in patients with stroke and AF who were taking oral anticoagulants (OACs). Methods Subjects were selected from patients enrolled in the Korean ATrial fibrillaTion EvaluatioN regisTry in Ischemic strOke patieNts (K-ATTENTION) nationwide multicenter registry between 2013 and 2015. Patients were excluded if they were not taking OACs, had no brain imaging data, or had intracranial bleeding directly related to the index stroke. Major bleeding was defined according to International Society of Thrombosis and Haemostasis criteria. Cox regression analyses were performed to assess the associations between clinical variables and major bleeding and Kaplan-Meier estimates were performed to analyze event-free survival. Results Of a total of 3,213 patients, 1,414 subjects (mean age of 72.6 years, 52.5% males) were enrolled in this study. Major bleeding was reported in 34 patients during the median follow-up period of 1.73 years. Multivariable analysis demonstrated that initial National Institutes of Health Stroke Scale scores (hazard ratio [HR] 1.07, p=0.006), hypertension (HR 3.18, p=0.030), persistent AF type (HR 2.51, p=0.016), and initial hemoglobin level (HR 0.74, p=0.001) were independently associated with major bleeding risk. Except for hypertension, these associations remained significant after adjusting for the HAS-BLED score. Intracranial atherosclerosis presented a trend of association without statistical significance (HR 2.21, p=0.050). Conclusions This study found that major bleeding risk was independently associated with stroke-specific factors in anticoagulated patients with stroke and AF. This has the clinical implication that baseline characteristics of patients with stroke and AF should be considered in secondary prevention, which would bring the net clinical benefit of balancing recurrent stroke prevention with minimal bleeding complications.
참고문헌 (28)
- Wolf PA, "Atrial fibrillation as an independent risk factor for stroke : the Framingham Study", Stroke, 22, pp.983~988 (1991)
- Yu I, "CHADS2, CHA2DS2-VASc, ATRIA, and Essen stroke risk scores in stroke with atrial fibrillation: a nationwide multicenter registry study", Medicine(Baltimore), 100, pp.e24000~ (2021)
- Lane DA, "Stroke and bleeding risk stratification in atrial fibrillation : a critical appraisal", Eur Heart J Suppl, 22(Suppl O), pp.O14~O27 (2020)
- Lip GY, "Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation : the HAS-BLED(hypertension, abnormal renal", liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs, J Am Coll Cardiol, pp.2011, 57[DOI]
- Borre ED, "Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation : a systematic review", Thromb Haemost, 118, pp.2171~2187 (2018)
- Caldeira D, "Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation : a systematic review and meta-analysis", J Interv Card Electrophysiol, 40, pp.277~284 (2014)
- Zhu W, "The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation : a systematic review and meta-analysis", Clin Cardiol, 38, pp.555~561 (2015)
- Song TJ, "Characteristics and factors for short-term functional outcome in stroke patients with atrial fibrillation, nationwide retrospective cohort study", Front Neurol, 10, pp.1101~ (2019)
- Hindricks G, "2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS) : the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC)Developed with the special contribution of the European Heart Rhythm Association(EHRA)of the ESC", Eur Heart J, 42, pp.373~498 (2021)
- Schulman S, "Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients", J Thromb Haemost, 3, pp.692~694 (2005)
- Lane DA, "Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation", Circulation, 126, pp.860~865 (2012)
- Chao TF, "Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study", Int J Cardiol, 254, pp.157~161 (2018)
- Pisters R, "A novel user-friendly score(HAS-BLED)to assess 1-year risk of major bleeding in patients with atrial fibrillation : the Euro Heart Survey", Chest, 138, pp.1093~1100 (2010)
- Landefeld CS, "Major bleeding in outpatients treated with warfarin : incidence and prediction by factors known at the start of outpatient therapy", Am J Med, 87, pp.144~152 (1989)
- Hughes M, "Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation : a systematic review", QJM, 100, pp.599~607 (2007)
- Hylek EM, "Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin : the ARISTOTLE Trial(apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) : predictors, characteristics, and clinical outcomes", J Am Coll Cardiol, 63, pp.2141~2147 (2014)
- Ogata T, "Gastrointestinal bleeding in acute ischemic stroke : recent trends from the fukuoka stroke registry", Cerebrovasc Dis Extra, 4, pp.156~164 (2014)
- Fu J, "Factors affecting the occurrence of gastrointestinal bleeding in acute ischemic stroke patients", Medicine(Baltimore), 98, pp.e16312~ (2019)
- Schirmer CM, "Gastrointestinal prophylaxis in neurocritical care", Neurocrit Care, 16, pp.184~193 (2012)
- Bassand JP, "Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes", Eur Heart J, 31, pp.50~58 (2010)
- Nagao K, "Prognostic impact of baseline hemoglobin levels on long-term thrombotic and bleeding events after percutaneous coronary interventions", J Am Heart Assoc, 8, pp.e013703~ (2019)
- Harskamp RE, "Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation : a meta-analysis of randomised controlled trials", Acta Cardiol, 77, pp.191~195 (2022)
- Ishii M, "Relationship of hypertension and systolic blood pressure with the risk of stroke or bleeding in patients with atrial fibrillation : the Fushimi AF Registry", Am J Hyperten, 30, pp.1073~1082 (2017)
- 방오영, "Intracranial Atherosclerosis: Current Understanding and Perspectives", 대한뇌졸중영문학회지, 16(1), pp.27~35 (2014), 대한뇌졸중학회[DOI]
- Park JH, "Atherosclerotic burden and vascular risk in stroke patients with atrial fibrillation", Stroke, 52, pp.1662~1672 (2021)
- Roskell NS, "Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists : a systematic review of randomized and observational studies", Europace, 15, pp.787~797 (2013)
- Pan KL, "Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease : a systematic review and meta-analysis", J Am Heart Assoc, 6, pp.e005835~ (2017)
- Forslund T, "Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation : a population-based cohort study", Europace, 20, pp.420~428 (2018)